LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles.
性状
Solid
IC50 & Target[1][2]
Annexin A2 (AnxA2)
体外研究(In Vitro)
In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Application of LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) of angiogenesis demonstrates suppression of the angiogenic responses. Treatment with the LCKLSL peptide significantly decreases the vascular length. At a dose of 5 μg/mL, the LCKLSL peptide significantly decreases the number of vascular branches, junctions and end-points. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and lightPowder -80°C 2 years;-20°C 1 year
SequenceShortening
LCKLSL
Sequence
Leu-Cys-Lys-Leu-Ser-Leu
参考文献
[1]. Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.
溶解度数据
In Vitro: DMSO : 25 mg/mL (35.10 mM; Need ultrasonic)H2O : 10 mg/mL (14.04 mM; Need ultrasonic)配制储备液